Pharmafile Logo
Pharmafocus logo
Advanced Search

COPD

Showing 15 posts of 79 posts found.

Munro & Forster win PRCA Health and Wellbeing Award

November 28, 2011
Medical Communications COPD, ERS, Munro & Forster, PRCA

Healthcare comms agency Munro & Forster has won an industry award for its innovative World Spirometry Day Campaign for the …

News

FDA delays decision on Novartis’ COPD drug

March 23, 2011
Sales and Marketing COPD, Novartis, Onbrez Breezhaler, QAB149, bronchodilator, chronic obstructive pulmonary disease, indacterol

The FDA has delayed its licence decision on Novartis’ once-daily COPD treatment QAB149 by three months. The review process will …

News

Novartis’ COPD drug recommended for FDA approval

March 10, 2011
Sales and Marketing Arcapta Neohaler, COPD, Novartis, Onbrez Breezhaler, QAB143, chronic obstructive pulmonary disease, indacterol

Novartis has won the backing of an FDA advisory committee for its chronic obstructive pulmonary disease (COPD) treatment QAB149. The …

News

Forest’s COPD drug approved in US

March 3, 2011
Sales and Marketing COPD, Daliresp, Daxas, Forest, Forest Laboratories, chronic obstructive pulmonary disease, roflumilast

Daliresp (roflumilast) has been approved by the FDA to treat severe chronic obstructive pulmonary disease. Forest Laboratories’ once-daily pill is …

News
Blog footer

Digital Pharma: Pfizer and Boehringer’s online COPD awareness

November 12, 2010
Medical Communications Boehringer Ingelheim, COPD, Digital Pharma blog, Managing COPD, NICE, Pfizer, Spiriva, chronic obstructive pulmonary disease

Pfizer and Boehringer Ingelheim have launched an online campaign to publicise the latest NICE guidelines on COPD to healthcare professionals …

News
Pfizer and Boehringer's COPD campaign website

Pfizer and Boehringer pilot COPD campaign

November 9, 2010
Medical Communications Boehringer Ingelheim, COPD, Pfizer, Salford, chronic bronchitis, chronic obstructive pulmonary disease, emphysema

Pfizer and Boehringer Ingelheim have mobilised a soap opera star, painted rugby players and a special ‘breathing bus’ for a …

News
GSK’s Seretide/Advair

New COPD and asthma treatments jostle for market space

October 6, 2010
Research and Development, Sales and Marketing COPD, Daxas, Onbrez Breezhaler, Revolair, asthma

Competition in the field of COPD and asthma is hotting up, with new data for several key treatments recently unveiled. …

Feature

Extra phase II studies boost GSK’s Relovair

September 23, 2010
COPD, GlaxoSmithKline, Relovair, asthma

GlaxoSmithKline has conducted additional phase II trials on its asthma/COPD drug Relovair to answer a number of safety and efficacy …

News

Novartis hails longer-lasting COPD drug

September 20, 2010
Research and Development, Sales and Marketing COPD, Novartis, Onbrez Breezhaler

A phase III treatment for COPD has demonstrated superior results over GSK’s established Serevent (salmeterol). Data from Novartis’ INSIST study …

News
Novartislr

Novartis’ COPD contender cleared in EU

December 4, 2009
Sales and Marketing COPD, Novartis, resp

 Novartis has been given a green light in the European Union to sell its Onbrez respiratory drug, allowing the firm …

News

GSK begins phase III COPD trials

October 28, 2009
Research and Development, Sales and Marketing COPD, GSK, GlaxoSmithKline, Seretide, Theravance, resp, respiratory

GlaxoSmithKline and San Francisco biopharma firm Theravance have begun a phase III trial to develop a new treatment for chronic …

News

GP targets drive up COPD prescribing

May 27, 2009
Sales and Marketing COPD, NHS, qof

Respiratory drugs saw the biggest growth in GP prescribing in England in 2008, thanks to new COPD targets.The rapid growth …

News

Phase III drug superior to Spiriva, says Novartis

May 21, 2009
Research and Development, Sales and Marketing COPD, Novarits

Novartis says its COPD treatment has shown significant benefits over two established rivals, and could form the cornerstone of a …

News

Spiriva leads charge for Boehringer

April 23, 2009
Sales and Marketing Boehringer, COPD

News

Almirall in talks with potential asthma partners

February 26, 2009
Sales and Marketing Almirall, COPD

Spanish pharma company Almirall is in discussions with potential partners for one of its asthma drugs following positive trial results. …

News

Latest content

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023

Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment

November 24, 2023